Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

Abstract

Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients. We conclude that analysis of recurrent tumor samples may improve the predictive value of ER and PR assays.